GLG News by HIV Specialists (US)

The key point in this article is that the author shows a connection between Community Acquired clostridium difficile infections & lack of antimicrobial use. For example, the widespread use of ant-acids ie; proton pump inhibitors. This article is helpful because delineating some of the risk factors...

TODAY MANY PATIENTS HAS DILEMA TO BUY FOOD OR DRUG               EFECTIVENESS OF GENERIC DRUG ALSO MAIL ORDER OR LOCAL PHARMACY COST

Medicare will use a very small carrot to entice financially stressed physicians to employ electronic prescribing technology.  Later on, Medicare will switch to the stick and penalize physicians who don't use such a system.

Cuts in Medicare put off for the time being, though only under substantial political pressure.  This band-aid will last only so long; real reform of the flawed sustainable growth rate eludes us yet again!  Bush and friends still favor the insurance lobby over senior's access to their phys...

Drug makers complain that the FDA's 'safety focus' slows down their development of new medications.  They would love to see accelerated approvals; next they'll get the immunity from lawsuits that device makers have already received!

Any finished medication that a Chinese company tries to bring to the US (or European) market will face tremendous scrutiny.  Look for Indian generic manufacturers (e.g. Ranbaxy, Dr Reddy's) to maintain their competitive edge due to their track record of safety.  Eventually, lower cost generics...

These 3 cases add to a number of others which have appeared in the news media, raising public awareness regarding procedures performed by unlicensed practitioners.  Such cases are unlikely to impact the blooming market in FDA-approved fillers when administered by medical professionals.

For too long big pharma has dictated which drugs will come to market and what they will cost.  The entire American healthcare system is literally collapsing because of two costs:  medications and bureacracy.  Expect more payers to look for ways to bring down costs in the fu...

In the two large phase 3 registration trials of albinterferon alfa-2b (Albuferon, Human Genome Sciences), called ACHIEVE-1 and ACHIEVE-2/3, several patients in the arm using Albuferon 1200 mcg per 2 weeks + RBV were found to have serious pulmonry adverse events.  Such serious events were not...

   The IDEAL study compared combination therapy of ribavirin (RBV) plus PEG-Intron (Schering) at 1.5 mcg/kg weekly vs. 1.0 mcg/kg vs. Pegasys (Roche) 180 mcg weekly in treatment-naive HCV genotype 1 patients.  The primary outcome of SVR rate was similar:  40% vs. 38% vs. 41%. ...